Methods and devices for renal nerve blocking

• US 9,968,611 B2
• Filed: 10/08/2015
• Issued: 05/15/2018
• Est. Priority Date: 04/08/2002
• Status: Expired due to Fees

• Current Assignee: Medtronic Ardian Luxembourg SARL (Medtronic Plc)
• Original Assignee: Medtronic Ardian Luxembourg SARL (Medtronic Plc)
• Inventors: Gelfand, Mark, Levin, Howard R.
• Primary Examiner(s): BOCKELMAN, MARK
• Application Number:
  US14/878,371
• Publication Number:
  US 20160095862A1
• Time in Patent Office: 950 Days
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 31/529 forming part of bridged ring systems
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/0012 Galenical forms characterised by the site of application
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61L 29/146 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61M 2005/14513 with secondary fluid driving or regulating the infusion
• CPC Class Codes: A61M 2205/05 combined with other kinds of therapy
• CPC Class Codes: A61M 2205/50 with microprocessors or computers
• CPC Class Codes: A61M 2210/1082 Kidney
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/145 using pressurised reservoirs, e.g. pressurised by means of pistons
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61N 1/0551 Spinal or peripheral nerve electrodes
• CPC Class Codes: A61N 1/326 for promoting growth of cells, e.g. bone cells
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/36117 for treating hypertension
• CPC Class Codes: A61N 1/3627 : for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

Drug eluting implants for targeted delivery of a nerve blocking agent to inhibit neural traffic along renal nerves of a human patient.

Claims

1. A method of treating a human patient diagnosed with at least one of hypertension, heart failure, acute myocardial infarction, renal disease, or chronic renal failure, the method comprising:

extravascularly positioning a drug eluting device proximate to a renal nerve innervating a kidney of the patient; and

delivering a nerve blocking agent from the drug eluting device to inhibit neural traffic along the renal nerve to and from the kidney of the patient,

wherein inhibiting neural traffic along the renal nerve beneficially treats the patient by modulating at least one of urine production, blood pressure, fluid retention, renin secretion, renal blood flow, waste excretion, and sodium retention in the patient.

2. The method of claim 1 wherein extravascularly positioning a drug eluting device proximate to a renal nerve comprises positioning a matrix carrying a nerve blocking agent proximate to the renal nerve.

3. The method of claim 2 wherein positioning a matrix carrying a nerve blocking agent proximate to the renal nerve comprises positioning at least one of a gel, patch, microsphere, suspension, and solution proximate to the renal nerve.

4. The method of claim 1, wherein extravascularly positioning the drug eluting device comprises positioning the drug eluting device under guidance imaging.

5. The method of claim 4 wherein extravascularly positioning the drug eluting device under guidance imaging comprises positioning the drug eluting device under fluoroscopic guidance.

6. The method of claim 1 wherein extravascularly positioning a drug eluting device proximate a renal nerve comprises positioning a biodegradable polymer proximate the renal nerve.

7. The method of claim 1 wherein extravascularly positioning a drug eluting device proximate a renal nerve comprises positioning a surface eroding polymer proximate the renal nerve.

8. The method of claim 1 wherein inhibiting neural traffic along the renal nerve comprises denervating the kidney of the patient.

9. The method of claim 1 wherein inhibiting neural traffic along the renal nerve comprises ablating the renal nerve via the nerve blocking agent.

10. The method of claim 1 wherein inhibiting neural traffic along the renal nerve further results in a reduction of systemic sympathetic tone in the patient.